455.HK
Tianda Pharmaceuticals Ltd
Price:  
0.16 
HKD
Volume:  
30,000
Hong Kong | Pharmaceuticals

455.HK WACC - Weighted Average Cost of Capital

The WACC of Tianda Pharmaceuticals Ltd (455.HK) is 5.7%.

The Cost of Equity of Tianda Pharmaceuticals Ltd (455.HK) is 5.95%.
The Cost of Debt of Tianda Pharmaceuticals Ltd (455.HK) is 5.5%.

RangeSelected
Cost of equity5.1% - 6.8%5.95%
Tax rate6.8% - 9.8%8.3%
Cost of debt4.0% - 7.0%5.5%
WACC4.7% - 6.7%5.7%
WACC

455.HK WACC calculation

CategoryLowHigh
Long-term bond rate2.9%3.4%
Equity market risk premium6.0%7.0%
Adjusted beta0.370.42
Additional risk adjustments0.0%0.5%
Cost of equity5.1%6.8%
Tax rate6.8%9.8%
Debt/Equity ratio
0.380.38
Cost of debt4.0%7.0%
After-tax WACC4.7%6.7%
Selected WACC5.7%

455.HK's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for 455.HK:

cost_of_equity (5.95%) = risk_free_rate (3.15%) + equity_risk_premium (6.50%) * adjusted_beta (0.37) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.